Tech Surge Helps Wall Street End Quarter Up

Bets on a strong economic rebound supported Wall Street during the quarter even as investors got jittery about a retail trading frenzy, a spike in Treasury yields and a US hedge fund going bust.

On Wednesday, the benchmark S&P 500 came close to hitting 4,000 for the first time. The S&P 500 technology index led sector gains, while the energy sector fell and was the weakest sector on the day.

"The trend we're seeing today is investors rotating back into growth-oriented names that have gotten a little bit beaten up over the past few weeks or so due to underlying rotation toward the economic reopening stocks," said Michael Sheldon, chief investment officer at RDM Financial Group at Hightower.

Some cyclical sectors could also be taking a breather from their rise because of recent strength in the US dollar, he said.

For the quarter, the Nasdaq underperformed the other two major indexes as investors swapped growth-oriented stocks with underpriced shares deemed to benefit most from a full economic reopening. High-flying tech names have been hit by a surge in US 10-year bond yields.

The Dow Jones Industrial Average fell 0.26 percent, to 32,982, the S&P 500 gained 0.36 percent, to 3,973 and the Nasdaq Composite added 1.54 percent, to 13,247.

For the quarter, the Dow gained about 8 percent, the S&P 500 rose 6 percent and the Nasdaq increased 3 percent. For the month, the Dow added about 7 percent, the S&P 500 rose 4 percent and the Nasdaq gained just 0.4 percent.

Biden's US$3 trillion-US$4 trillion infrastructure package will target traditional projects like roads and bridges alongside investments in the electric vehicle market.

The size and scale of the proposal, as well as how to pay for it, should set the stage for the next partisan clash in Congress.

Apple rose 1.9 percent after brokerage UBS upgraded the stock to "buy" on stable long-term demand for iPhones with better authorised service providers.

Walgreens Boots Alliance advanced 3.6 percent after raising its 2021 profit forecast on higher sales at its US retail pharmacy stores. (Reuters)